What is Prostatype Genomics AB (publ) (PROGEN.ST)?

Prostatype Genomics AB (publ) (PROGEN.ST) is a stock in the Healthcare sector, Medical - Diagnostics & Research industry. View full analysis on Stocks360.

Prostatype Genomics AB (publ) (PROGEN.ST)

Stock analysis · STO · Healthcare · Medical - Diagnostics & Research

Market Cap

N/A

PE (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

Beta

1.40

Day Range

N/A

52-wk Range

N/A

Avg Volume

N/A

Volume

N/A

Prostatype Genomics AB (publ) (PROGEN.ST) is a publicly traded company in the Healthcare sector. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Aug 17, 2023

EPS $-0.08 vs est. $-0.10

Beat by $0.02

Proprietary Signals

Signal snapshot temporarily unavailable.

About Prostatype Genomics AB (publ)

Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Score, and Tumor Stage to determine a specific P-score. This advanced diagnostic tool is built upon a vast database of prostate cancer patients, providing crucial support for patients and medical practitioners when deciding on treatment strategies. Founded in 2007, the company is headquartered in Solna, Sweden.